Published in final edited form as: Am J Cardiol. 2017 Feb 15;119(4):501-507. doi: 10.1016/j.amjcard.2016.10.038 -3 -New-generation drug-eluting stents (DES) are frequently implanted in complex anatomic and clinical settings 1, 2 and are recommended for unrestricted use across patient and lesion subsets. 3, 4 Studies analyzing bare-metal stents (BMS) and early-generation DES showed less favorable outcomes in patients treated for complex ("off-label") indications. [4] [5] [6] In contrast, few data exist regarding new-generation DES in complex patients and lesions, and are limited by short-to mid-term follow-up durations. 7, 8 Biodegradable polymer DES (BP-DES) were conceived to overcome safety issues of early-generation durable polymer (DP) DES, as polymer remnants within the arterial wall may be implicated in late stent thrombosis or delayed restenosis. The BIOSCIENCE randomized trial reported non-inferiority of the ultra-thin strut BP sirolimus-eluting stent (BP-SES) compared with DP everolimus-eluting stent (DP-EES). 9 Other studies showed clinical 10, 11 and angiographic non-inferiority 12 of thin-strut BP platforms.
Whether these performance profiles are maintained in patients undergoing complex interventions remains unknown. This study sought to determine the impact of patient and lesion complexity on 2-year clinical outcomes following revascularization with new-generation DES, and to compare the safety and efficacy of ultrathin-strut BP-SES vs. DP-EES in relation to complexity status in a large-scale randomized trial with minimal exclusion criteria.
Methods
This is a pre-specified analysis of the BIOSCIENCE trial (NCT01443104), 9,13 a prospective, multicenter trial that compared an ultrathin strut stent covered with a BP releasing sirolimus (Orsiro;
Biotronik AG, Bülach, Switzerland) with a thin strut DP-EES (XIENCE PRIME/Xpedition®; Abbott Vascular, Santa Clara, CA, USA). 13 Briefly, patients with stable coronary artery disease (CAD) or acute coronary syndrome (ACS) and at least 1 lesion with diameter stenosis >50% (de novo or restenosis) in a native vessel or bypass graft with reference vessel diameter between 2.25 and 4.0 mm were eligible for inclusion. There were no restrictions to the number of treated lesions or vessels. The study was approved by institutional ethics committees of all participating sites. All patients provided written informed consent. 
Results
Out of 2,119 patients enrolled, 911 complex patients (43%) were allocated to BP-SES (n=487) or DP-EES (n=424). Simple patients (1,208; 57%) were randomized to BP-SES (n=576) or DP-EES (n=632) patients, complex patients were older, more commonly female, with more frequent history of previous revascularization ( Table 1) . Variables were well-balanced between the BP-SES and DP-EES arms for both complex and simple patients (Supplementary Table 1) . Complex patients had a higher number of lesions treated, and received more stents per lesion with greater length and diameter ( Table 2) .
The primary endpoint, TLF at 2 years, occurred in 128 complex patients (14.5%) vs. 86 simple patients (7.4%) (RR 2.05, 95% CI 1.56-2.69; p=0.001). Consistent differences were observed in all components of the primary endpoint ( Table 3) Table 4 ). The DP-EES was associated with lower cardiac mortality among simple patients, but with higher cardiac mortality among complex patients ( Table 4) .
Discussion
The findings of the present study can be summarized as follows. First, patient and lesion complexity was associated with higher long-term risk of stent-related and patient-related adverse events following PCI with new-generation DES. Second, complexity had a durable adverse impact extending beyond the first year of follow-up. Third, primary safety and efficacy endpoints were comparable between the ultra-thin strut BP-SES and DP-EES, consistently among complex and simple patients. These findings add to previous investigations that assessed complex interventions using earlier-generation devices. 5, 6 They also build upon studies that demonstrated comparable efficacy and safety profiles of thin-strut BP-DES vs.
DP-EES but did not address the possibly interrelating effect of patient and lesion complexity.
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While on-label FDA indication for coronary DES is limited to low-risk, stable CAD patients with single simple lesions, PCI is frequently performed in more complex settings. Observational studies with primarily early-generation DES showed marked attenuation of the benefits of DES with off-label vs.
on-label use. 4, 5 New-generation DES have improved the safety and efficacy of PCI 3, 4 ; however, there are limited data regarding long-term performance of new-generation DES in complex settings. 7 The present analysis from a broadly inclusive contemporary trial uniquely addressed the impact of patient and lesion complexity on long-term clinical outcomes with the unrestricted use of 2 new-generation DES.
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Interventions in complex patients were associated with less-favorable outcomes including 2-fold higher risk of TLF, 3-fold higher mortality, and increased risk of all ischemic endpoints, particularly among patients with multiple concomitant complexity features. These differences emerged following the early phase (30 days), they extended beyond the first year and were at least as pronounced during the second year of follow-up. These observations may have implications for long-term risk stratification and patient management, as complex patients are likely to benefit more from aggressive, sustained secondary prevention therapies. 17 Defining characteristics of complexity in this study included comorbidities with a well-established role in the pathobiology of atherosclerotic disease and in-stent restenosis (insulin-treated diabetes, renal dysfunction); clinical conditions portending sustained atherothrombotic risk (acute STEMI); and challenging anatomic settings known to adversely affect procedural and longer-term PCI outcomes. These complexity features have been closely linked to adverse PCI outcomes in previous relevant reports focusing on earlier devices.
5,8
The rates of definite stent thrombosis within 2 years (0.9%) is comparable with other studies with new-generation DES, 18 but was 4-fold increased among complex vs. simple patients. Whether complex patients might benefit from more prolonged dual antiplatelet therapy or potent P2Y12 inhibitors even in non-ACS settings merits investigation in dedicated studies, also accounting for individual bleeding risk.
These findings require cautious interpretation owing to the small numbers of events, and the possibly heterogeneous ischemic risk among patients encompassed in our complexity definition.
Decision-making regarding the preferred modality of coronary revascularization (PCI vs. CABG) is a challenging process accounting for patient-related factors, anatomic configurations, and procedural feasibility. 3 The present findings should be interpreted in view of the following considerations. First, PCI is the cornerstone for management of acute STEMI (the most common complexity feature in this study), whereas CABG has very limited role in this context. 3 Second, improvements in stent technologies appear to have narrowed the outcome gap between CABG and PCI in patients with advanced, complex disease. 19 Third, several of the complexity characteristics are also known to adversely affect prognosis following This study has limitations. First, our findings are presented as hypothesis-generating only, being a post hoc analysis of a trial not designed to assess outcomes in relation to complexity. Second, the study was powered for the primary endpoint but is underpowered to detect differences in individual components or rare events, such as stent thrombosis. Third, this analysis was not designed to address the causal vs.
associative interrelation of complexity factors with adverse outcomes. Fourth, although the definition of complexity was not pre-defined, the present complexity analysis was pre-specified in the study protocol. 13 Finally, the biodegradable polymer of the BP-SES degrades over a period of 12 to 24 months; hence, potential differences in outcomes may only emerge during very long-term (more than 2-year) follow-up.
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Figures Figure 1. Frequency of complexity characteristics (A) and number of complexity features per patient (B)
among complex patients (n=911).
-17 - BP-SES = biodegradable polymer sirolimus-eluting stent; CAD = coronary artery disease; DP-EES = durable polymer everolimus-eluting stent; PCI = percutaneous coronary intervention. Abbreviations as in Table 3 .
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